Skip to main content

Table 3 Prevalence of KRAS and GNAS mutations in patients with IPMN according to the ethnicity, mutation detection, and specimen type

From: KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis

Category KRAS mutation GNAS mutation
No. of studies No. of cases Prevalence (%) (95 % CI) P value No. of studies No. of cases Prevalence (%) (95 % CI) P value
Overall 33 1253 60.9 (54.3–67.1)   11 835 55.8 (48.5–62.8)  
Ethnicity     0.106     0.429
 Caucasian 15 532 55.1 (45.2–64.7)   7 374 58.4 (48.8–67.4)  
 Asian 18 721 66.0 (56.9–74.0)   4 461 52.6 (41.8–63.1)  
Detection method     0.207     0.552
 Sequencing 27 1017 59.0 (52.1–65.6)   9 694 54.9 (47.0–62.5)  
 Non-sequencing 6 236 69.0 (54.6–80.4)   2 141 60.9 (42.3–76.9)  
Specimen typea     0.095     0.147
 Tissue 27 929 58.9 (51.3–66.1)   8 533 61.0 (52.0–69.4)  
 Cyst fluid or pancreatic juice 8 324 71.4 (58.4–81.7)   5 302 50.3 (39.1–61.5)  
  1. CI confidence interval
  2. aTwo studies were performed in both tissue and cyst fluid